Nationwide Children's Hospital

This study is testing a new vaccine designed to train the immune system to fight aggressive brain cancers in children and young adults. It will enroll about 120 patients aged 3 to 39 with newly diagnosed high-grade glioma, diffuse intrinsic pontine glioma (DIPG), or recurrent med…

This study is testing a drug called Lutathera in children and young adults (ages 4 to 39) with aggressive brain or spinal cord tumors that have come back or gotten worse after standard treatments. Lutathera is a targeted radiation therapy that seeks out and attaches to specific m…

This study is testing whether adding infusions of a special type of immune cell, called a natural killer (NK) cell, to a standard chemotherapy regimen can help children and young adults whose bone or soft tissue cancers have returned or not responded to prior treatments. The main…

This study aims to find better treatments for children and young adults newly diagnosed with aggressive brain tumors. Researchers will analyze the genetic makeup of each patient's tumor to match them with a targeted therapy that might work best for their specific cancer. The goal…

This study is testing an oral medication called ACT001 in children and young adults with two types of aggressive brain tumors: diffuse intrinsic pontine glioma (DIPG) and H3K27-altered high-grade glioma (HGG). The main goals are to see if the drug is safe and if it helps patients…

This study is testing a targeted drug called lorlatinib in children and young adults (ages 1-21) newly diagnosed with aggressive brain tumors (high-grade gliomas) that have specific genetic changes called ALK or ROS1 fusions. The main goals are to see if the drug can control the …

This study is testing two different drug combinations to see if they can help children and young adults with aggressive brain tumors live longer. The trial is for patients who have just finished radiation therapy. One group receives two drugs (ribociclib and everolimus), while an…

This early-stage study is testing a drug called larotrectinib in children and young adults (up to age 21) newly diagnosed with aggressive brain tumors that have a specific genetic feature called an NTRK fusion. The main goals are to see if the drug can control the tumor and to ch…

This study is testing whether the drug anakinra can calm dangerous overactive inflammation in children whose organs are failing due to sepsis. Researchers will give the drug or a placebo to 500 critically ill children in intensive care units. The goal is to see if controlling thi…

This study is testing an oral medication called binimetinib for children and young adults with a recurrent brain tumor called adamantinomatous craniopharyngioma. The goal is to see if the drug can shrink the tumor and control its growth, especially for patients whose cancer has r…

This study is testing whether an existing arthritis drug called Actemra (tocilizumab) can help control a rare and difficult-to-treat brain tumor in children and young adults. The trial will enroll up to 38 patients aged 1 to 39 years who have a recurrent or progressive tumor call…

This study is testing an online program called PLAY, designed to support caregivers of young children who have finished active cancer treatment. The program provides weekly online modules and video coaching sessions over three months to help caregivers manage stress, improve pare…